Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

Simonetta Viviani, MD, Francesco Spina, MD, Arabella Mazzocchi, Maria Galbiati, Flavio Crippa, MD, Lucia Farina, MD PhD, Anna Guidetti, MD, Massimo Di Nicola, Liliana Franca Devizzi, MD, Paola Matteucci, MD, Michele Magni, MD, Anna Dodero, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2016) 128 (22): 3009.

https://doi.org/10.1182/blood.V128.22.3009.3009

Published: 2016

Journal Articles

Brentuximab Vedotin (BV) an Effective Treatment for Autologous (ASCT) and/or Allogeneic (alloSCT) Transplant naïve Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) : A retrospective Single-Institution Study

Simonetta Viviani, MD, Serena Dalto, MD, Paola Matteucci, MD, Massimo Di Nicola, MD, Anna Guidetti, MD, Liliana Devizzi, MD, Michele Magni, MD, Anna Dodero, MD, Lucia Farina, MD, Francesco Spina, MD, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2014) 124 (21): 5428.

https://doi.org/10.1182/blood.V124.21.5428.5428

Published: 2014

Journal Articles

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

Jacopo Mariotti, MD, Anna Guidetti, MD, Michele Magni, MD, Paola Matteucci, MD, Liliana Devizzi, MD, Andrés J.M. Ferreri, Paolo Corradini, MD, Anna Dodero, MD, Amalia De Renzo, Alessandro Massimo Gianni, MD, Massimo Di Nicola, MD

Blood (2014) 124 (21): 1734.

https://doi.org/10.1182/blood.V124.21.1734.1734

Published: 2014

Journal Articles

Potent In Vivo Anti-Tumor Activity Of Extracellular Vesicles Isolated From Genetically Engineered Primary Mesenchymal Stromal Cells Expressing The Trans-Membrane TNF-Related Apoptosis-Inducing Ligand (TRAIL)

Stefano Buttiglieri, PhD, Carmelo Carlo-Stella, MD, Tiziana Spatola, BiolSc, Roberta Pulito, BiolSc, Luigi Naldini, MD, PhD, Andrea Anichini, PhD, Michele Magni, MD, Arianna Giacomini, PhD, Corrado Tarella, MD, Alessandro M. Gianni, MD

Blood (2013) 122 (21): 1658.

https://doi.org/10.1182/blood.V122.21.1658.1658

Published: 2013

Journal Articles

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Blood (2013) 122 (21): 551.

https://doi.org/10.1182/blood.V122.21.551.551

Published: 2013

Journal Articles

MiR-146a up-Regulation Is Associated with Anti-Tumor Activity of Pan-Histone Deacetylase Inhibitor ITF2357 (Givinostat®) in Human Burkitt's Lymphoma

Roberta Zappasodi, PhD, Alessandra Cavanè, Marilena V Iorio, Monica Tortoreto, Giusi Ruggiero, Michele Magni, MD, Carmelo Carlo-Stella, MD, Elda Tagliabue, Franco Zunino, Carlo M. Croce, MD, Alessandro M. Gianni, MD, Massimo Di Nicola, MD

Blood (2011) 118 (21): 2729.

https://doi.org/10.1182/blood.V118.21.2729.2729

Published: 2011

Journal Articles

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Marco Ruella, MD, Andrea Filippi, MD, Anna DI Russo, MD, Daniele Caracciolo, MD, Paola Matteucci, MD, Michele Magni, MD, Massimo Di Nicola, MD, Umberto Ricardi, MD, Vittorio Montefusco, MD, Guido Parvis, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD, Liliana Devizzi, MD

Blood (2011) 118 (21): 3699.

https://doi.org/10.1182/blood.V118.21.3699.3699

Published: 2011

Journal Articles

Autologous Peripheral Blood Stem-Cell (PBSC) Collection Is Not Impaired by Bortezomib-Thalidomide-Dexamethasone (VTD) Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)

Blood (2011) 118 (21): 317.

https://doi.org/10.1182/blood.V118.21.317.317

Published: 2011

Journal Articles

Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study

Blood (2011) 118 (21): 1647.

https://doi.org/10.1182/blood.V118.21.1647.1647

Published: 2011

Journal Articles

Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma

Silvia Locatelli, PhD, Arianna Giacomini, PhD, Anna Guidetti, MD, Loredana Cleris, PhD, Michele Magni, MD, Massimo Di Nicola, MD, Roberta Mortarini, PhD, Alessandro M Gianni, MD, Andrea Anichini, PhD, Carmelo Carlo-Stella, MD

Blood (2011) 118 (21): 1653.

https://doi.org/10.1182/blood.V118.21.1653.1653

Published: 2011

Journal Articles

Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target

Roberta Zappasodi, Italia Bongarzone, Gaia C. Ghedini, Lorenzo Castagnoli, Antonello D. Cabras, Antonella Messina, Monica Tortoreto, Claudio Tripodo, Michele Magni, Carmelo Carlo-Stella, Alessandro M. Gianni, Serenella M. Pupa, Massimo Di Nicola

Blood (2011) 118 (16): 4421–4430.

https://doi.org/10.1182/blood-2011-06-364570

Published: 2011

Includes: Supplemental data

Journal Articles

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.

Anna Guidetti, MD, Carmelo Carlo-Stella, MD, Marco Ruella, MD, Rosalba Miceli, MD, Liliana Devizzi, MD, Daniela Sia, PhD, Silvia Locatelli, PhD, Arianna Giacomini, PhD, Michele Magni, MD, Paola Matteucci, MD, Stefano Buttiglieri, PhD, Alessandra Risso, PhD, Luigi Mariani, MD, Roberto Passera, PhD, Massimo Di Nicola, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD

Blood (2010) 116 (21): 1289.

https://doi.org/10.1182/blood.V116.21.1289.1289

Published: 2010

Journal Articles

Human CD34 + cells engineered to express membrane-bound tumor necrosis factor–related apoptosis-inducing ligand target both tumor cells and tumor vasculature

Cristiana Lavazza, Carmelo Carlo-Stella, Arianna Giacomini, Loredana Cleris, Marco Righi, Daniela Sia, Massimo Di Nicola, Michele Magni, Paolo Longoni, Marco Milanesi, Maura Francolini, Annunziata Gloghini, Antonino Carbone, Franca Formelli, Alessandro M. Gianni

Blood (2010) 115 (11): 2231–2240.

https://doi.org/10.1182/blood-2009-08-239632

Published: 2010

Includes: Supplemental data

Journal Articles

Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL).

Anna Guidetti, MD, Carmelo Carlo-Stella, MD, Liliana Devizzi, MD, Paola Matteucci, MD, Alfonso Marchianò, MD, Rodolfo Lanocita, MD, Michele Magni, MD, Anna Dodero, MD, Corrado Tarella, MD, Massimo Di Nicola, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD

Blood (2009) 114 (22): 1658.

https://doi.org/10.1182/blood.V114.22.1658.1658

Published: 2009

Journal Articles

Male Gender, Quality of Grafted Cells, Advanced Age, Rituximab and Radiotherapy Are the Main Factors That Variously Influence the Occurrence of Secondary Malignancies Following High-Dose Therapy and Autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Survey in 1,347 Lymphoma Patients.

Blood (2009) 114 (22): 519.

https://doi.org/10.1182/blood.V114.22.519.519

Published: 2009

Journal Articles

A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ?.

Blood (2009) 114 (22): 882.

https://doi.org/10.1182/blood.V114.22.882.882

Published: 2009

Journal Articles

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study

Massimo Di Nicola, Roberta Zappasodi, Carmelo Carlo-Stella, Roberta Mortarini, Serenella M. Pupa, Michele Magni, Liliana Devizzi, Paola Matteucci, Paola Baldassari, Fernando Ravagnani, Antonello Cabras, Andrea Anichini, Alessandro M. Gianni

Blood (2009) 113 (1): 18–27.

https://doi.org/10.1182/blood-2008-06-165654

Published: 2009

Includes: Supplemental data

Journal Articles

Monitoring of Post-Transplant Hematopoiesis in Patients Receiving High-Dose Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) with Autograft: Lack of Detection of Remarkable Abnormalities.

Anna Guidetti, MD, Carmelo Carlo-Stella, MD, Alberto Rocci, MD, Liliana Devizzi, MD, Daniela Sia, PhD, Adele Testi, PhD, Michele Magni, MD, Massimo Di Nicola, MD, Paola Matteucci, MD, Alessandra Risso, PhD, Marco Ruella, MD, Corrado Tarella, MD, Alesandro M. Gianni, MD

Blood (2008) 112 (11): 2158.

https://doi.org/10.1182/blood.V112.11.2158.2158

Published: 2008

Journal Articles

Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome

Blood (2008) 112 (11): 778.

https://doi.org/10.1182/blood.V112.11.778.778

Published: 2008

Journal Articles

Preclinical Rationale for the Use of the Multikinase Inhibitor Sorafenib in the Treatment of Human Lymphomas

Carmelo Carlo-Stella, MD, Cristiana Lavazza, PhD, Arianna Giacomini, PhD, Loredana Cleris, Daniela Sia, PhD, Paolo Longoni, Marco Milanesi, Michele Magni, MD, Massimo Di Nicola, MD, Annunziata Gloghini, PhD, Antonino Carbone, MD, Marco Righi, MD, Franca Formelli, PhD, Alessandro M. Gianni, MD

Blood (2008) 112 (11): 2605.

https://doi.org/10.1182/blood.V112.11.2605.2605

Published: 2008

NARROW

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

Brentuximab Vedotin (BV) an Effective Treatment for Autologous (ASCT) and/or Allogeneic (alloSCT) Transplant naïve Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) : A retrospective Single-Institution Study

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

Potent In Vivo Anti-Tumor Activity Of Extracellular Vesicles Isolated From Genetically Engineered Primary Mesenchymal Stromal Cells Expressing The Trans-Membrane TNF-Related Apoptosis-Inducing Ligand (TRAIL)

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

MiR-146a up-Regulation Is Associated with Anti-Tumor Activity of Pan-Histone Deacetylase Inhibitor ITF2357 (Givinostat®) in Human Burkitt's Lymphoma

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Autologous Peripheral Blood Stem-Cell (PBSC) Collection Is Not Impaired by Bortezomib-Thalidomide-Dexamethasone (VTD) Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)

Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study

Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma

Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.

Human CD34 + cells engineered to express membrane-bound tumor necrosis factor–related apoptosis-inducing ligand target both tumor cells and tumor vasculature

Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL).

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study

Monitoring of Post-Transplant Hematopoiesis in Patients Receiving High-Dose Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) with Autograft: Lack of Detection of Remarkable Abnormalities.

Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome

Preclinical Rationale for the Use of the Multikinase Inhibitor Sorafenib in the Treatment of Human Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only